Sanofi rolls out new Fluzone shots; Alexion's Soliris driving myasthenia gravis market growth;

> Sanofi's ($SNY) vaccines division shipped its first doses of Fluzone for the 2015-2016 influenza season in the U.S. Release

> Alexion's ($ALXN) rare disease drug Soliris could drive the value of the myasthenia gravis market to $550 million by 2024, GlobalData figures. Report

> Misuse of the anticoagulant warfarin is causing deaths and injuries in nursing homes, a ProPublica investigation found. Report

> Taiwan's pharma market is expected to rise to $8.4 billion by 2020, despite ongoing political tensions with China. Release

> Sarepta Therapeutics ($SRPT) is looking to buy another drug to treat Duchenne muscular dystrophy in its race with BioMarin Pharmaceutical ($BMRN) in the field. Report

And Finally... The FDA warned about the cardiovascular risks of NSAIDs last week, and experts now say they should be used sparingly. Report